Baseline patient characteristics (N = 2124)
| Characteristic . | Data . |
|---|---|
| Age, median (range), y | 63 (18-83) |
| Age, y | |
| ≤40 | 276 (13) |
| 41-60 | 650 (31) |
| 61-75 | 1026 (48) |
| >75 | 172 (8) |
| Males | 1198 (56) |
| Ann Arbor stage III/IV | 1321 (62) |
| ECOG performance status ≥ 2 | 334 (16) |
| LDH ratio | |
| <1× ULN | 877 (41) |
| 1-3× ULN | 1031 (49) |
| >3× ULN | 216 (10) |
| Extranodal sites > 1 | 469 (22) |
| Extranodal involvement of major organ* | 811 (38) |
| IPI risk group | |
| Low (0-1) | 730 (34) |
| Low-intermediate (2) | 480 (23) |
| High-intermediate (3) | 486 (23) |
| High (4-5) | 428 (20) |
| R-IPI risk group | |
| Very good (0) | 183 (9) |
| Good (1-2) | 1027 (48) |
| Poor (3-5) | 914 (43) |
| NCCN-IPI risk group | |
| Low (0-1) | 281 (13) |
| Low-intermediate (2-3) | 864 (41) |
| High-intermediate (4-5) | 764 (36) |
| High (6-8) | 215 (10) |
| Study | |
| LNH03-2B9 | 132 (6) |
| LNH03-6B10 | 441 (21) |
| LNH98511 | 98 (5) |
| MegaCHOEP12 | 202 (10) |
| MinT13 | 380 (18) |
| RICOVER-6014 | 474 (22) |
| UCL15 | 397 (19) |
| Induction regimen† | |
| R-CHOP | 1542 (73) |
| CHOP-like + R | 380 (18) |
| R-CHOEP | 101 (5) |
| R-MegaCHOEP | 101 (5) |
| Characteristic . | Data . |
|---|---|
| Age, median (range), y | 63 (18-83) |
| Age, y | |
| ≤40 | 276 (13) |
| 41-60 | 650 (31) |
| 61-75 | 1026 (48) |
| >75 | 172 (8) |
| Males | 1198 (56) |
| Ann Arbor stage III/IV | 1321 (62) |
| ECOG performance status ≥ 2 | 334 (16) |
| LDH ratio | |
| <1× ULN | 877 (41) |
| 1-3× ULN | 1031 (49) |
| >3× ULN | 216 (10) |
| Extranodal sites > 1 | 469 (22) |
| Extranodal involvement of major organ* | 811 (38) |
| IPI risk group | |
| Low (0-1) | 730 (34) |
| Low-intermediate (2) | 480 (23) |
| High-intermediate (3) | 486 (23) |
| High (4-5) | 428 (20) |
| R-IPI risk group | |
| Very good (0) | 183 (9) |
| Good (1-2) | 1027 (48) |
| Poor (3-5) | 914 (43) |
| NCCN-IPI risk group | |
| Low (0-1) | 281 (13) |
| Low-intermediate (2-3) | 864 (41) |
| High-intermediate (4-5) | 764 (36) |
| High (6-8) | 215 (10) |
| Study | |
| LNH03-2B9 | 132 (6) |
| LNH03-6B10 | 441 (21) |
| LNH98511 | 98 (5) |
| MegaCHOEP12 | 202 (10) |
| MinT13 | 380 (18) |
| RICOVER-6014 | 474 (22) |
| UCL15 | 397 (19) |
| Induction regimen† | |
| R-CHOP | 1542 (73) |
| CHOP-like + R | 380 (18) |
| R-CHOEP | 101 (5) |
| R-MegaCHOEP | 101 (5) |
Unless otherwise indicated, data are n (%).
R-CHOEP, rituximab plus cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; R-MegaCHOEP, R-CHOEP with escalated doses of cyclophosphamide, etoposide, and doxorubicin.
Involvement of the bone marrow, central nervous system, liver or gastrointestinal system, or lung.
R-CHOP was administered every 14 or 21 days over 6 to 8 cycles,9-11,14,15 CHOP-like + R was administered over 6 cycles,13 and R-CHOEP or R-MegaCHOEP was administered over 8 cycles.12